Earnings Feed
Start Free
SUPERNUS PHARMACEUTICALS, INC.·4

Feb 25, 4:36 PM ET

GEMAYEL GEORGES 4

4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Feb 25, 2026

Insider Transaction Report

Form 4
Period: 2026-02-23
SUPERNUS PHARMACEUTICALS, INC.SUPN
GEMAYEL GEORGES
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-23$12.98/sh+15,000$194,700→ 33,684 total
  • Award

    Common Stock

    2026-02-24+4,475→ 38,159 total
  • Exercise/Conversion

    Director Stock Option (Right to Buy)

    2026-02-23−15,000→ 0 total
    Exercise: $12.98From: 2017-03-01Exp: 2026-03-01→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    [F1][F2]
    2026-02-24−4,475→ 0 total
    → Common Stock (4,475 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  • [F2]These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.
Signature
/s/ Timothy C. Dec, as attorney-in-fact|2026-02-25

Documents

1 file
  • 4
    wk-form4_1772055360.xmlPrimary

    FORM 4